Nexplanon (Etonogestrel)

Etonogestrel, the active ingredient in Nexplanon, is a synthetic progestogen presented as a 68 mg subdermal implant (rod) for subcutaneous administration. It provides long‑acting hormonal contraception by releasing a steady low dose of progestin, thereby preventing ovulation and pregnancy in women of reproductive age through continuous systemic exposure over three years.

GNH USA supplies Nexplanon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Nexplanon, a progestogen‑only hormonal contraceptive, is indicated for the prevention of pregnancy.

- Prevention of pregnancy: provides highly effective, reversible contraception for up to three years. - Women who cannot use estrogen‑containing methods: offers a safe alternative without estrogen exposure. - Family planning: enables long‑term birth control for women of reproductive age.

Nexplanon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular vaginal bleeding or spotting. - Absence of periods (amenorrhea). - Headache. - Breast tenderness.

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism. - Severe allergic reaction (anaphylaxis). - Infection or abscess at the insertion site.

Before prescribing Nexplanon, clinicians should consider several safety measures.

- Screen for contraindications: ensure the patient has no history of thromboembolic disorders. - Assess hormonal sensitivity: avoid use in women with known estrogen‑dependent tumors. - Monitor menstrual changes: counsel about possible irregular bleeding patterns. - Check insertion site: observe for signs of infection, migration, or extrusion. - Confirm non‑pregnant status: perform a pregnancy test prior to insertion. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nexplanon can interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy. - Rifampin and other strong CYP3A4 inducers: may lower etonogestrel levels. - Certain antiretroviral protease inhibitors (e.g., ritonavir): may alter hormone metabolism.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase hormone concentrations. - St. John’s wort: may modestly decrease contraceptive effectiveness. - Concurrent hormonal therapies (e.g., estrogen patches): may raise the risk of thromboembolic events.